Table 2.
Characteristics of patients in the cardiovascular outcome trials and a general T2D population from four European countries
| DECLARE‐TIMI 58 (dapagliflozin) References 6, 16 | CANVAS (canagliflozin) Reference 3 | EMPA‐REG OUTCOME (empagliflozin) Reference 5 | VERTIS‐CV (ertugliflozin) References 3 | General T2D population | |
|---|---|---|---|---|---|
| Number of patients | 17 160 | 10 142 | 7020 | 8237 | 803 836 |
| Age, years | 63.8 | 63.3 | 63.1 | 64.4 | 67.0 |
| Sex, female | 37% | 36% | 29% | 30% | 43% |
| Cardiovascular disease | 41% | 66% | 99% | 99% | 34% |
| Heart failure | 10% | 14% | 10% | 22% | 14% |